Malaria Vaccine: Pfs25-OMPC/MERCK ALUMINUM ADJUVANT

尽管Pfs25已经被证明可以诱导抗体来阻止蚊子体内寄生虫的发展，但这种蛋白的免疫原性很差。因此，基于Pfs25的TBV开发面临的主要挑战是提高免疫原性和反应寿命。OMPC是脑膜炎奈瑟氏菌B亚群的外膜蛋白复合体，已被用作商业许可的多糖疫苗的载体，以提高多糖的免疫原性。在与默克研究实验室的合作下，我们开发了一种将Pfs25与OMPC结合的方法。用小鼠、兔和恒河猴评价Pfs25-OMPC结合物的免疫原性和免疫反应寿命。在体外膜喂养实验中评价了偶联物的传递阻断活性。生产了多个共轭批次，并对其进行了评估，以证明接合过程的稳健性。

Though Pfs25 has been shown to induce antibodies that can block parasite development in mosquitoes, the protein is poorly immunogenic. Thus the major challenge facing Pfs25-based TBV development is to increase the immunogenicity and response longevity. OMPC, the Outer Membrane Protein Complex of the Neisseria meningitides subgroup B, has been used as a carrier in commercially licensed polysaccharide vaccines to increase polysaccharide immunogenicity. In collaboration with Merck Research Laboratories, we have developed a process to conjugated Pfs25 with OMPC. The immunogenicity and the response longevity of the Pfs25-OMPC conjugate was evaluated in mice, rabbits, and rhesus monkeys. The conjugates transmission blocking activity was evaluated in an ex-vivo membrane feeding assay. Multiple conjugate batches were produced and evaluated to demonstrate the robustness of the conjugation process.